RenovoRX announced that they had a Pre-submission meeting for European Orphan Drug Designation, as well as sales contract signoff and first catheter shipments to 1-2 additional TIGeR-PaC clinical sites. RenovoRX obtained US orphan drug status for their catheter solution and they announced a $10M Series D round, $7.9M of which has already been closed. Boston Scientific led the round, and was joined by btov PartnersAstia Angels, the Angels' Forum, the Halo Fund III, L.P., Golden Seeds, and Acorn Campus Taiwan.